These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 20508227)
1. Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. Böhm S; Hess D; Gillessen S; Brändle M Diabetes Care; 2010 Jun; 33(6):e82. PubMed ID: 20508227 [No Abstract] [Full Text] [Related]
2. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525 [TBL] [Abstract][Full Text] [Related]
6. Biphasic insulin aspart 30 treatment improves glycemic control among patients with type 2 diabetes in Saudi Arabia and the Gulf region. Ayad NM; Fattah WA; Bakry H Saudi Med J; 2008 Jun; 29(6):919-20. PubMed ID: 18521482 [No Abstract] [Full Text] [Related]
7. [Drug therapy of type 2 diabetes with 1.26g/l fasting blood glucose (see above)]. Slama G; Selam JL; Elgrably F; Reach G Diabetes Metab; 1999 Nov; 25(5):436-40. PubMed ID: 10592869 [No Abstract] [Full Text] [Related]
8. Insulin therapy for maximal glycemic control in type 2 diabetes mellitus. Spellman CW J Am Osteopath Assoc; 2007 Jul; 107(7):260-9. PubMed ID: 17682113 [TBL] [Abstract][Full Text] [Related]
9. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Maughan BL; Pal SK; Gill D; Boucher K; Martin C; Salgia M; Nussenzveig R; Liu T; Hawks JL; Batten J; Nachaegari G; Stephenson R; Lowrance W; Jones J; Dechet C; Agarwal N Oncologist; 2018 Dec; 23(12):1413-e151. PubMed ID: 30575560 [TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Hanefeld M; Forst T Lancet; 2010 Jun; 375(9733):2196-8. PubMed ID: 20609956 [No Abstract] [Full Text] [Related]
12. Self-monitoring of blood glucose for type 2 diabetes 2. Bloomgarden Z; Ning G J Diabetes; 2015 Sep; 7(5):593-4. PubMed ID: 25940569 [No Abstract] [Full Text] [Related]
13. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin. Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736 [TBL] [Abstract][Full Text] [Related]
14. Clinical perspectives in type 2 diabetes care: optimizing glycemic control with insulin therapy. Diabetes Educ; 2005; Suppl():1-14; quiz 15-6. PubMed ID: 15786628 [No Abstract] [Full Text] [Related]
15. [The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results]. Levy JC; Cull CA; Stratton IM; Holman RR; Turner RC Journ Annu Diabetol Hotel Dieu; 1993; ():123-37. PubMed ID: 8331860 [No Abstract] [Full Text] [Related]
16. Role of Continuous Glucose Monitoring in Insulin-Requiring Patients with Diabetes. Welsh JB Diabetes Technol Ther; 2018 Jun; 20(S2):S242-S249. PubMed ID: 29916736 [No Abstract] [Full Text] [Related]
20. There is level 1 evidence for intensive glycemic control for reducing the progression of diabetic retinopathy in persons with type 2 diabetes. Chew EY Endocrine; 2015 May; 49(1):1-3. PubMed ID: 25722012 [No Abstract] [Full Text] [Related] [Next] [New Search]